Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.

SEC Filings

For all investor or media inquiries, visit https://www.adaptimmune.com/contact.

Filing date	Description	Form	Filing Group	View
May 24, 2023	Filing of certain prospectuses and communications in connection with business combination transactions	425	Other	0001193125-23-153018.pdf 0001193125-23-153018.rtf 0001193125-23-153018.xls View HTML
May 30, 2023	Filing of certain prospectuses and communications in connection with business combination transactions	425	Other	0001104659-23-066058.pdf 0001104659-23-066058.rtf View HTML
Feb 15, 2019	Form of prospectus disclosing information facts events covered in both forms 424B1 424B3	424B4	Registration Statements	0001193125-19-042430.pdf 0001193125-19-042430.rtf 0001193125-19-042430.xls View HTML
Jul 27, 2020	Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3	424B5	Registration Statements	0001193125-20-199694.pdf 0001193125-20-199694.rtf 0001193125-20-199694.xls View HTML
Jul 29, 2020	Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3	424B5	Registration Statements	0001193125-20-202547.pdf 0001193125-20-202547.rtf 0001193125-20-202547.xls View HTML
Jan 19, 2021	Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3	424B5	Registration Statements	0001193125-21-010752.pdf 0001193125-21-010752.rtf 0001193125-21-010752.xls View HTML
Jan 21, 2021	Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3	424B5	Registration Statements	0001193125-21-012567.pdf 0001193125-21-012567.rtf 0001193125-21-012567.xls View HTML
Apr 30, 2021	Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3	424B5	Registration Statements	0001193125-21-145133.pdf 0001193125-21-145133.rtf View HTML
Feb 13, 2019	FWP	FWP	Other	0001193125-19-038130.pdf 0001193125-19-038130.rtf 0001193125-19-038130.xls View HTML
Feb 13, 2019	Initial filing by director officer or owner of more than ten percent.	3	3,4,5	0000899243-19-003480.pdf 0000899243-19-003480.rtf View HTML

Data provided by Kaleidoscope.

Adaptimmune (ADAP)

Adaptimmune

The time to redefine the treatment of cancer is now.

About Us

Redefining the treatment of solid tumor cancers.

Adaptimmune is committed to treating the most challenging solid tumors using a proprietary cell therapy platform that harnesses a patient's cells to combat their cancer.

Using a personalized approach that has the potential to radically improve the patient experience.

We use cell therapy, a promising yet complex area of science, to engineer a person’s own cells to fight cancer.

A future where a single infusion could reshape cancer care.

We are a fully integrated company on the verge of a new era. With our first BLA submitted to the FDA, we are aiming to commercialize the  first engineered T-cell therapy in solid tumors to help improve cancer treatment.